ArticleFrontiers in oncology2025
Intratumoral habitat and peritumor radiomics for progression risk stratification of patients with soft tissue sarcoma: a multicenter study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Relationships among fear of progression, avoidance coping, and post-traumatic growth in adult patients with lymphoma: A multi-center cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Pretreatment CT radiomics for prediction of pathological complete response after neoadjuvant chemoimmunotherapy in NSCLC: a multicenter study incorporating habitat analysis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To establish and validate a radiomics nomogram that incorporated tumor habitat and peritumor features to predict tumor progression in patients with soft tissue sarcoma (STS). Methods: MRI data (fat-suppressed T2-weighted and contrast-enhanced fat-suppressed T1-weighted images) from 148 STS patients treated in four institutions were retrospectively enrolled. Patients were divided into a training cohort (n = 108) and validation cohort (n = 40). K-means clustering was applied to split intratumoral voxels into three habitats according to signal intensity values. A large number of radiomics features were extracted from numerous tumor-associated regions (tumor lesion, peritumor, tumor expansion, and intratumoral habitats) to construct a series of radiomics signatures. A nomogram integrating clinical predictors and radiomics signature was established and its value for predicting progression was validated. Results: The nomogram yielded superior prediction performance and less predictive error in the validation cohort (C-index, 0.777; median area under the receiver operating characteristic curve, 0.808; integrated Brier score, 0.135). When patients were stratified according to risk of progression (low and high) based on the nomogram in both the training and validation cohorts, Kaplan-Meier survival analysis demonstrated significant differences in progression-free survival between the groups. In addition, it could attach incremental value to histopathological grade system in progression risk evaluation. Conclusion: A nomogram based on intratumoral habitat and peritumor radiomics predicts tumor progression in STS patients and stratifies them according to risk of progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.